Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering
February 09, 2022 18:10 ET
|
Statera Biopharma
FORT COLLINS, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering
February 06, 2022 22:59 ET
|
Statera Biopharma
FORT COLLINS, Colo., Feb. 06, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease
December 29, 2021 07:32 ET
|
Statera Biopharma
FORT COLLINS, Colo., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID
December 20, 2021 16:03 ET
|
Statera Biopharma
Initial Study to Evaluate Pharmacokinetics, Biomarkers and Safety of STAT-205 Targeting Preliminary Data 2022 FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq:...
Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod
December 01, 2021 07:32 ET
|
Statera Biopharma
FORT COLLINS, Colo., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma Provides Third Quarter 2021 Financial and Corporate Update
November 15, 2021 16:03 ET
|
Statera Biopharma
FORT COLLINS, Co., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma, Inc. to Report Third Quarter 2021 Financial Results
November 09, 2021 07:32 ET
|
Statera Biopharma
FORT COLLINS, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma Honors Pancreatic Cancer Awareness Month
November 01, 2021 07:32 ET
|
Statera Biopharma
FORT COLLINS, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-19
October 19, 2021 07:32 ET
|
Statera Biopharma
Researchers at Loma Linda University Health to Evaluate Pharmacokinetics, Biomarkers and Safety of STAT-205 FORT COLLINS, Colo., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq:...
Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference
October 06, 2021 07:33 ET
|
Statera Biopharma
FORT COLLINS, Colo., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...